What is Glatiramer acetate?
Category: Prescription Drugs
Most popular types: Copaxone Glatopa
Glatiramer acetate combines four amino acids including L-alanine, L-glutamic acid, L-lysine and L-tyrosine. It is used for Relapsing-Remitting Multiple Sclerosis (RRMS) to reduce the frequency and severity of relapses. It is administered as a subcutaneous injection.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple sclerosis | 20231 | 3049 | |
| General health | 73 | 50 | |
| Stiffness/spasticity | 51 | 20 | |
| Fatigue | 28 | 17 | |
| Pain | 11 | 2 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 296 | |
| Moderate | 502 | |
| Mild | 1398 | |
| None | 896 |
Commonly reported side effects and conditions associated with Glatiramer acetate
| Side effect | Patients | Percentage |
|---|---|---|
| Injection site pain | 346 | |
| Injection site itching | 294 | |
| Lumps and bumps | 279 | |
| Bruising | 158 | |
| Itching | 98 | |
| Injection site swelling | 82 |
Why patients stopped taking Glatiramer acetate
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Did not seem to work | 1037 | |
| Side effects too severe | 809 | |
| Doctor's advice | 785 | |
| Other | 558 | |
| Expense | 162 | |
| Personal research | 143 | |
| Change in health plan coverage | 85 | |
| Course of treatment ended | 42 |
Duration
Stopped taking Glatiramer acetate
| Duration | Patients | Percentage |
|---|---|---|
| Less than 1 month | 197 | |
| 1 - 6 months | 416 | |
| 6 months - 1 year | 415 | |
| 1 - 2 years | 426 | |
| 2 - 5 years | 590 | |
| 5 - 10 years | 303 | |
| 10 years or more | 103 |
What people switch to and from
Patients started taking Glatiramer acetate after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Interferon beta-1a IM Injection (Avonex) | 72 | |
| Interferon beta-1a SubQ injection (Rebif) | 62 | |
| Dimethyl fumarate (Tecfidera) | 47 | |
| Interferon beta-1b SubQ Injection (Betaseron) | 34 | |
| Natalizumab (Tysabri) | 17 |
Patients stopped taking Glatiramer acetate and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Dimethyl fumarate (Tecfidera) | 153 | |
| Natalizumab (Tysabri) | 96 | |
| Fingolimod (Gilenya) | 80 | |
| Teriflunomide (Aubagio) | 58 | |
| Interferon beta-1a SubQ injection (Rebif) | 40 |
Last updated: